Wen Su1, Huijing Liu2, Yanyan Jiang3, Shuhua Li4, Ying Jin5, Chuanzhu Yan6, Haibo Chen7. 1. Research Institute of Neuromuscular and Neurodegenerative Disease, Department of Neurology, Qilu Hospital, Shandong University, Jinan, China; Neurology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, PR China. Electronic address: suwendy@126.com. 2. Neurology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, PR China. Electronic address: liuhuijing.2007@163.com. 3. Neurology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, PR China. Electronic address: jiangyanyan8888@163.com. 4. Neurology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, PR China. Electronic address: lsh1992@sina.com. 5. Neurology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, PR China. Electronic address: jinying2000@126.com. 6. Research Institute of Neuromuscular and Neurodegenerative Disease, Department of Neurology, Qilu Hospital, Shandong University, Jinan, China. Electronic address: chuanzhuyancn@163.com. 7. Neurology Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Dong Dan, Beijing, 100730, PR China. Electronic address: chenhb_bjh@hotmail.com.
Abstract
OBJECTIVE: To understand the distribution of Parkinson's disease questionnaire-39 (PDQ-39) scores in Parkinson's disease (PD) patients with or without depression, and to analyze the factors that influence the quality of life of PD patients. MATERIALS AND METHODS: 300 PD patients were enrolled. Patients' general information and the results of assessments including UPDRS, H-Y, HAMD, HAMA, ADL and PDQ-39 were collected. They were divided into depression group and non-depression group according to HAMD score. The relationship between PD-related depression and quality of life and the factors that influence the quality of life of PD patients were analyzed based on PDQ-39 score. RESULTS: 111 patients with depression (37.0 %) and 189 patients without depression (63.0 %) were enrolled. The scores of PDQ-39 summary index (PDQ-39 SI) in the depression group were significantly higher than those in the non-depression group in all domains (P < 0.05). Patients in the depression group had a longer disease duration (6.89 ± 4.70 vs. 5.52 ± 4.12, P < 0.038), a higher UPDRS-III score (30.1 ± 13.55 vs. 25.2 ± 11.73, P < 0.001), and a higher H-Y stage level (2.41 ± 0.853 vs. 2.13 ± 0.707, P < 0.001), compared with patients in the non-depression group. All factors including age, disease duration, UPDRS-III, H-Y stage, HAMD score and HAMA score, may independently affected PDQ-39SI in PD patients, among which HAMD had the greatest effect. HAMD and HAMA were correlated with PDQ-39 in its all eight domains. CONCLUSION: PD patients with psychological problems such as anxiety and depression may lead to a significant decline in the quality of life of patients in all domains.
OBJECTIVE: To understand the distribution of Parkinson's disease questionnaire-39 (PDQ-39) scores in Parkinson's disease (PD) patients with or without depression, and to analyze the factors that influence the quality of life of PD patients. MATERIALS AND METHODS: 300 PD patients were enrolled. Patients' general information and the results of assessments including UPDRS, H-Y, HAMD, HAMA, ADL and PDQ-39 were collected. They were divided into depression group and non-depression group according to HAMD score. The relationship between PD-related depression and quality of life and the factors that influence the quality of life of PD patients were analyzed based on PDQ-39 score. RESULTS: 111 patients with depression (37.0 %) and 189 patients without depression (63.0 %) were enrolled. The scores of PDQ-39 summary index (PDQ-39 SI) in the depression group were significantly higher than those in the non-depression group in all domains (P < 0.05). Patients in the depression group had a longer disease duration (6.89 ± 4.70 vs. 5.52 ± 4.12, P < 0.038), a higher UPDRS-III score (30.1 ± 13.55 vs. 25.2 ± 11.73, P < 0.001), and a higher H-Y stage level (2.41 ± 0.853 vs. 2.13 ± 0.707, P < 0.001), compared with patients in the non-depression group. All factors including age, disease duration, UPDRS-III, H-Y stage, HAMD score and HAMA score, may independently affected PDQ-39SI in PD patients, among which HAMD had the greatest effect. HAMD and HAMA were correlated with PDQ-39 in its all eight domains. CONCLUSION: PD patients with psychological problems such as anxiety and depression may lead to a significant decline in the quality of life of patients in all domains.
Authors: Carmen M Labandeira; Maria G Alonso Losada; Rosa Yáñez Baña; Maria I Cimas Hernando; Iria Cabo López; Jose M Paz González; Maria J Gonzalez Palmás; Cristina Martínez Miró; Diego Santos García Journal: Adv Ther Date: 2021-09-15 Impact factor: 3.845